RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Advancing performance measures for use of medications in substance abuse treatment.
Mark, T., Thomas, C. P., Garnick, D., Horgan, C., Gmyrek, A., Chalk, M., Gelber, S., Albright, J., Capoccia, V., Harris, A., Harwood, H., Greenberg, PE., Un, H., Oros, M., Stringer, M., & Thatcher, J. (2012). Advancing performance measures for use of medications in substance abuse treatment.Journal of Substance Abuse Treatment, 40(1), 35-43. Article PMC2997925. https://doi.org/10.1016/j.jsat.2010.08.005
Performance measures have the potential to drive high quality health care. However, technical and policy challenges exist in developing and implementing measures to assess substance use disorder (SUD) pharmacotherapy. Of critical importance in advancing performance measures for use of SUD pharmacotherapy is recognition that different measurement approaches may be needed in the public and private sectors, and will be determined by the availability of different data collection and monitoring systems. In 2009, the Washington Circle convened a panel of nationally recognized insurers, purchasers, providers, policy makers, and researchers to address this topic. The charge of the panel was to identify opportunities and challenges in advancing use of SUD pharmacotherapy performance measures across a range of systems. This paper summarizes those findings by identifying a number of critical themes related to advancing SUD pharmacotherapy performance measures, highlighting examples from the field, and recommending actions for policy makers.
